These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27900797)

  • 1. Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
    Masko EM; Alfaqih MA; Solomon KR; Barry WT; Newgard CB; Muehlbauer MJ; Valilis NA; Phillips TE; Poulton SH; Freedland AR; Sun S; Dambal SK; Sanders SE; Macias E; Freeman MR; Dewhirst MW; Pizzo SV; Freedland SJ
    Prostate; 2017 Apr; 77(5):446-457. PubMed ID: 27900797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
    Murphy SA; Cannon CP; Blazing MA; Giugliano RP; White JA; Lokhnygina Y; Reist C; Im K; Bohula EA; Isaza D; Lopez-Sendon J; Dellborg M; Kher U; Tershakovec AM; Braunwald E
    J Am Coll Cardiol; 2016 Feb; 67(4):353-361. PubMed ID: 26821621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
    Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
    Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
    Allott EH; Masko EM; Freedland AR; Macias E; Pelton K; Solomon KR; Mostaghel EA; Thomas GV; Pizzo SV; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):196-203. PubMed ID: 29795142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
    Garcia MM; Varela CG; Silva PF; Lima PR; Góes PM; Rodrigues MG; Silva Mde L; Ladeia AM; Guimarães AC; Correia LC
    Arq Bras Cardiol; 2016 Apr; 106(4):279-88. PubMed ID: 27142792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
    Feldman T; Koren M; Insull W; McKenney J; Schrott H; Lewin A; Shah S; Sidisin M; Cho M; Kush D; Mitchel Y
    Am J Cardiol; 2004 Jun; 93(12):1481-6. PubMed ID: 15194017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin but not ezetimibe reduces sympathetic activity despite similar reductions in cholesterol levels.
    Lewandowski J; Siński M; Puchalska L; Symonides B; Gaciong Z
    J Am Soc Hypertens; 2014 Oct; 8(10):715-23. PubMed ID: 25418493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
    Gordon JA; Midha A; Szeitz A; Ghaffari M; Adomat HH; Guo Y; Klassen TL; Guns ES; Wasan KM; Cox ME
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):21-7. PubMed ID: 26238234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice.
    Hildemann SK; Barho C; Karmann B; Darius H; Bode C
    Curr Med Res Opin; 2008 Oct; 24(10):2777-84. PubMed ID: 18721490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
    Assmann G; Kannenberg F; Ramey DR; Musliner TA; Gutkin SW; Veltri EP
    Curr Med Res Opin; 2008 Jan; 24(1):249-59. PubMed ID: 18053317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
    Holme I; Boman K; Brudi P; Egstrup K; Gohlke-Baerwolf C; Kesäniemi YA; Malbecq W; Rossebø AB; Wachtell K; Willenheimer R; Pedersen TR
    Am J Cardiol; 2010 Jun; 105(12):1802-8. PubMed ID: 20538134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMPROVE-IT: what have we learned?
    Banach M; Nikolic D; Rizzo M; Toth PP
    Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.